Previous close | 22.20 |
Open | 22.20 |
Bid | 21.00 x N/A |
Ask | 22.40 x N/A |
Day's range | 22.20 - 22.20 |
52-week range | 12.60 - 25.60 |
Volume | |
Avg. volume | 3 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Bicycle Therapeutics (BCYC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
The average of price targets set by Wall Street analysts indicates a potential upside of 77.2% in Bicycle Therapeutics (BCYC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Bicycle Therapeutics ( NASDAQ:BCYC ) First Quarter 2024 Results Key Financial Results Revenue: US$19.5m (up 299% from...